vs
JFrog Ltd（FROG）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是JFrog Ltd的1.4倍（$207.3M vs $145.3M），JFrog Ltd净利率更高（-10.5% vs -62.0%，领先51.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 25.2%），JFrog Ltd自由现金流更多（$49.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 20.4%）
JFrog Ltd是全球知名的DevOps技术服务商，面向科技、金融、零售、制造等多个行业客户，提供全链路软件发布、制品管理与安全解决方案，助力企业简化云、本地及混合部署环境下的应用开发与交付流程。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FROG vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $145.3M | $207.3M |
| 净利润 | $-15.2M | $-128.6M |
| 毛利率 | 77.9% | — |
| 营业利润率 | -14.7% | -54.7% |
| 净利率 | -10.5% | -62.0% |
| 营收同比 | 25.2% | 25.9% |
| 净利润同比 | 34.4% | 3.5% |
| 每股收益（稀释后） | $-0.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $145.3M | $207.3M | ||
| Q3 25 | $136.9M | $159.9M | ||
| Q2 25 | $127.2M | $166.5M | ||
| Q1 25 | $122.4M | $139.3M | ||
| Q4 24 | $116.1M | $164.6M | ||
| Q3 24 | $109.1M | $139.5M | ||
| Q2 24 | $103.0M | $147.0M | ||
| Q1 24 | $100.3M | $108.8M |
| Q4 25 | $-15.2M | $-128.6M | ||
| Q3 25 | $-16.4M | $-180.4M | ||
| Q2 25 | $-21.7M | $-115.0M | ||
| Q1 25 | $-18.5M | $-151.1M | ||
| Q4 24 | $-23.2M | $-133.2M | ||
| Q3 24 | $-22.9M | $-133.5M | ||
| Q2 24 | $-14.3M | $-131.6M | ||
| Q1 24 | $-8.8M | $-170.7M |
| Q4 25 | 77.9% | — | ||
| Q3 25 | 77.4% | — | ||
| Q2 25 | 76.3% | — | ||
| Q1 25 | 75.3% | — | ||
| Q4 24 | 75.4% | — | ||
| Q3 24 | 75.0% | — | ||
| Q2 24 | 78.8% | — | ||
| Q1 24 | 79.5% | — |
| Q4 25 | -14.7% | -54.7% | ||
| Q3 25 | -15.8% | -106.9% | ||
| Q2 25 | -20.4% | -64.8% | ||
| Q1 25 | -18.8% | -102.6% | ||
| Q4 24 | -21.9% | -74.3% | ||
| Q3 24 | -27.4% | -94.6% | ||
| Q2 24 | -18.6% | -79.1% | ||
| Q1 24 | -16.6% | -151.9% |
| Q4 25 | -10.5% | -62.0% | ||
| Q3 25 | -12.0% | -112.8% | ||
| Q2 25 | -17.0% | -69.0% | ||
| Q1 25 | -15.1% | -108.5% | ||
| Q4 24 | -20.0% | -80.9% | ||
| Q3 24 | -21.0% | -95.7% | ||
| Q2 24 | -13.9% | -89.5% | ||
| Q1 24 | -8.8% | -156.8% |
| Q4 25 | $-0.13 | $-1.28 | ||
| Q3 25 | $-0.14 | $-1.81 | ||
| Q2 25 | $-0.19 | $-1.17 | ||
| Q1 25 | $-0.16 | $-1.57 | ||
| Q4 24 | $-0.21 | $-1.34 | ||
| Q3 24 | $-0.21 | $-1.40 | ||
| Q2 24 | $-0.13 | $-1.52 | ||
| Q1 24 | $-0.08 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $704.4M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $887.4M | $-80.0M |
| 总资产 | $1.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $704.4M | $421.0M | ||
| Q3 25 | $651.1M | $202.5M | ||
| Q2 25 | $611.7M | $176.3M | ||
| Q1 25 | $563.5M | $127.1M | ||
| Q4 24 | $522.0M | $174.0M | ||
| Q3 24 | $467.8M | $150.6M | ||
| Q2 24 | $591.3M | $480.7M | ||
| Q1 24 | $579.6M | $112.3M |
| Q4 25 | $887.4M | $-80.0M | ||
| Q3 25 | $859.4M | $9.2M | ||
| Q2 25 | $826.5M | $151.3M | ||
| Q1 25 | $800.0M | $144.2M | ||
| Q4 24 | $773.5M | $255.0M | ||
| Q3 24 | $756.2M | $346.8M | ||
| Q2 24 | $721.4M | $432.4M | ||
| Q1 24 | $707.8M | $140.3M |
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $997.1M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $50.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $49.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 34.3% | -48.6% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $142.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $50.7M | $-99.8M | ||
| Q3 25 | $30.2M | $-91.4M | ||
| Q2 25 | $36.1M | $-108.3M | ||
| Q1 25 | $28.8M | $-166.5M | ||
| Q4 24 | $49.1M | $-79.3M | ||
| Q3 24 | $27.6M | $-67.0M | ||
| Q2 24 | $16.7M | $-77.0M | ||
| Q1 24 | $17.5M | $-190.7M |
| Q4 25 | $49.9M | $-100.8M | ||
| Q3 25 | $28.8M | $-92.7M | ||
| Q2 25 | $35.5M | $-110.7M | ||
| Q1 25 | $28.1M | $-167.8M | ||
| Q4 24 | $48.5M | $-79.5M | ||
| Q3 24 | $26.7M | $-68.6M | ||
| Q2 24 | $16.0M | $-79.0M | ||
| Q1 24 | $16.6M | $-193.9M |
| Q4 25 | 34.3% | -48.6% | ||
| Q3 25 | 21.0% | -58.0% | ||
| Q2 25 | 27.9% | -66.5% | ||
| Q1 25 | 23.0% | -120.5% | ||
| Q4 24 | 41.8% | -48.3% | ||
| Q3 24 | 24.5% | -49.2% | ||
| Q2 24 | 15.5% | -53.7% | ||
| Q1 24 | 16.6% | -178.2% |
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 0.5% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 0.8% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FROG
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
